The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal ...

We hypothesized that 1) VEGF-A and its main functional receptor, VEGFR-2, are expressed in the fetal intestines; 2) one or both of these proteins are up-regulated in association with advancing ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

The HER family receptors form a signaling network that contributes to cancer progression. Angiogenesis plays a major role in cancer and VEGF-targeted agents have been shown to be useful in ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Gender differences define how the human brain ages, and telltale biomarkers in the blood may be strongly suggestive of ...

The following is a summary of “Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

Opthea Limited Sponsored ADR (OPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, ...